EREBAGEN LTD
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Watch this company
Get an email when Companies House records a change for Erebagen Ltd: status, filings, accounts, officers or owners. Free.
Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy
What does Erebagen Ltd sell?
Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.
Summary
EREBAGEN LTD is an active private limited company (company number 12537588) incorporated on 30 March 2020, registered in Kidlington. Its registered activity is research and experimental development on biotechnology (SIC 72110). Latest micro accounts cover the period ending 31 March 2026, showing net assets of £217k, with 3 employees on average. As micro-entity accounts, no profit and loss account is filed, so turnover and profit are not public. Net assets rose 1% on the prior period (£215k).
By net assets it sits in the upper half of 152 comparable companies in Oxford (median £10k, upper quartile £474k).
Ownership and control
No active person with significant control is registered.
- Dr Gregory Leonard Challis
- owns 25–50% of shares
- holds 25–50% of voting rights
- can appoint or remove directors
- Douglas Mark Roberts
- owns 25–50% of shares
- holds 25–50% of voting rights
- can appoint or remove directors
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
Key dates
- Incorporated
- 30 March 20206 yrs ago
- Next accounts due
- 31 December 2027in 433 days
- Confirmation statement due
- 13 April 2027in 171 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
Activity
- SIC 72110
- Research and experimental development on biotechnology
- SIC 72190
- Other research and experimental development on natural sciences and engineering
- Accounts type
- Micro Entity
- Size band
- MicroCompanies Act thresholds
Financials
| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 31 March 2026 | £217k | — | — | £9,008 | — | — | 3 |
| 31 March 2025 | £215k | — | — | £12k | — | — | 3 |
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing; micro-entity accounts contain no profit and loss account.
Filing and accounts signals
- Net assets above zeroNet assets £216,957 at 31 March 2026
- Current assets at least 1.5× creditors within one yearCurrent ratio 4.87
- Incorporated five or more years agoIncorporated 30 March 2020
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
Timeline
- Next accounts duein 433 days
- Confirmation statement duein 171 days
- Accounts period endNet assets £217k · micro accounts
- Accounts period endNet assets £215k · micro accounts
- Incorporated
Similar companies in Oxford
- ACT THERAPEUTICS LTDOxford · inc. Mar 2020
- LATUS THERAPEUTICS LIMITEDOxford · inc. Apr 2020
- METAGUIDEX LTDHeadington · inc. Apr 2020
- MEDIMAB BIOTHERAPEUTICS LTDAbingdon · inc. Mar 2020
- NEBUQUINE LIMITEDWitney · inc. Apr 2020
- OXFORD CANCER ANALYTICS LTDOxford · inc. Feb 2020
All companies incorporated on 30 March 2020 · in Mar 2020.
Reminders for EREBAGEN LTD
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.